Cargando…

Effects of 5-azacytidine on natural killer cell activating receptor expression in patients with refractory anemia with excess of blasts

Epigenetic drugs modify DNA methylation and are used in refractory anemia with excess of blasts (RAEB). These drugs may reactivate anti-oncogene expression and restore a normal phenotype instead of inducing antitumor toxicity, although they also have immunosuppressive effects on T-lymphocytes [1] In...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costello, Régis T., Leclercq, Amélie, Treut, Thérèse Le, Sanchez, Carole, Mercier, Delphine, Sébahoun, Gérard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327760/ https://www.ncbi.nlm.nih.gov/pubmed/25709892 http://dx.doi.org/10.1016/j.lrr.2014.09.004

Ejemplares similares

Expression of activating receptors on natural killer cells from AIDS-related lymphoma patients
por: Mercier-Bataille, Delphine, et al.
Publicado: (2014)

Bullous Pemphigoid in an Elderly Patient with Myelodysplastic Syndrome and Refractory Anemia Coupled with Excess of Blast
por: Lee, Yin Yin, et al.
Publicado: (2011)

Proteome Changes in the Plasma of Myelodysplastic Syndrome Patients with Refractory Anemia with Excess Blasts Subtype 2
por: Majek, Pavel, et al.
Publicado: (2014)

Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome
por: Májek, Pavel, et al.
Publicado: (2012)

Hematological Malignancies Escape from NK Cell Innate Immune Surveillance: Mechanisms and Therapeutic Implications
por: Farnault, Laure, et al.
Publicado: (2012)

Identification of genes underlying different methylation profiles in refractory anemia with excess blast and refractory cytopenia with multilineage dysplasia in myelodysplastic syndrome
por: Lee, Suee, et al.
Publicado: (2012)

Severe atypical herpes zoster as an initial symptom of fatal myelodysplastic syndrome with refractory anemia and blast excess (RAEB II)
por: Wollina, Uwe, et al.
Publicado: (2017)

Natural Killer Cells Modulation in Hematological Malignancies
por: Baier, Céline, et al.
Publicado: (2013)

Glutathione promotes the synergistic effects of venetoclax and azacytidine against myelodysplastic syndrome‑refractory anemia by regulating the cell cycle
por: Wang, Xiaobo, et al.
Publicado: (2023)

Localized ecthyma gangrenosum without sepsis in a neutropenic patient with a myelodysplastic syndrome—Refractory anemia with excess blasts type 2
por: Zanella, Anaïs, et al.
Publicado: (2019)

Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome
por: Sohlberg, Ebba, et al.
Publicado: (2015)

Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma
por: Laribi, Kamel, et al.
Publicado: (2022)

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
por: Jasra, Sakshi, et al.
Publicado: (2021)

Development of an Oral Form of Azacytidine: 2′3′5′Triacetyl-5-Azacytidine
por: Ziemba, Amy, et al.
Publicado: (2011)

Azacytidine Treatment for VEXAS Syndrome
por: Raaijmakers, Marc H. G. P., et al.
Publicado: (2021)

Natural Killer Cell Enteropathy With Extraintestinal Involvement: Presenting as Symptomatic Anemia
por: Panigrahi, Manas Kumar, et al.
Publicado: (2021)

Analysis of the Clinical Efficacy of Azacytidine + Venetoclax in the Treatment of Elderly Patients with Relapsed Refractory Acute Myeloid Leukemia
por: Wang, Wei, et al.
Publicado: (2022)

Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes
por: Raj, Kavita, et al.
Publicado: (2006)

Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells
por: Imanishi, Satoshi, et al.
Publicado: (2017)

Retracted: Analysis of the Clinical Efficacy of Azacytidine + Venetoclax in the Treatment of Elderly Patients with Relapsed Refractory Acute Myeloid Leukemia
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Incidence of blast phase in myelofibrosis according to anemia severity
por: Mora, Barbara, et al.
Publicado: (2023)

How to Diagnose Early 5-Azacytidine-Induced Pneumonitis: A Case Report
por: Misra, Srimanta Chandra, et al.
Publicado: (2017)

Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients
por: Truxova, Iva, et al.
Publicado: (2020)

Natural Killer Cells in Post-Transplant Lymphoproliferative Disorders
por: Nakid-Cordero, Cecilia, et al.
Publicado: (2021)

The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5‐azacytidine: Results from the Hellenic 5‐azacytidine registry
por: Diamantopoulos, Panagiotis, et al.
Publicado: (2019)

Cytogenetic effect of 5-azacytidine in patients with hematological malignancies
por: Tsuda, Jessica Romy, et al.
Publicado: (2011)

CNS Involvement in AML Patient Treated with 5-Azacytidine
por: Vasilatou, Diamantina, et al.
Publicado: (2014)

Suppressing nonsense—a surprising function for 5-azacytidine
por: Shao, Ada, et al.
Publicado: (2014)

Non-Genetically Improving the Natural Cytotoxicity of Natural Killer (NK) Cells
por: Villalba, Martin, et al.
Publicado: (2020)

Leukemia cutis with IDH1, DNMT3A and NRAS mutations conferring resistance to venetoclax plus 5-azacytidine in refractory AML
por: Wang, JingHan, et al.
Publicado: (2020)

Natural killer cells and natural killer T cells in Lyme arthritis
por: Katchar, Kia, et al.
Publicado: (2013)

Exploring the relationship between natural killer cells and cutaneous squamous cell carcinoma development
por: Ilyas, Muneeb, et al.
Publicado: (2017)

Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma
por: Lim, Jing Quan, et al.
Publicado: (2020)

Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome
por: Májek, Pavel, et al.
Publicado: (2013)

Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports
por: Rohon, Peter, et al.
Publicado: (2012)

Effects of 5-Azacytidine on Growth and Hypocrellin Production of Shiraia bambusicola
por: Ma, Yan Jun, et al.
Publicado: (2018)

A cat with myelodysplastic syndrome by administration of the methylation inhibitor Azacytidine
por: HISASUE, Masaharu, et al.
Publicado: (2021)

Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy
por: Xu, Ning, et al.
Publicado: (2021)

Roles of Natural Killer T Cells and Natural Killer Cells in Kidney Injury
por: Uchida, Takahiro, et al.
Publicado: (2019)

Antitumor Immunity Exerted by Natural Killer and Natural Killer T Cells in the Liver
por: Nakashima, Hiroyuki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lgaasq60k7rf5s7sf3321c54bm